Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic

Link to article at PubMed

Mayo Clin Proc. 2020 Nov;95(11):2467-2486. doi: 10.1016/j.mayocp.2020.08.030. Epub 2020 Aug 31.


A higher risk of thrombosis has been described as a prominent feature of coronavirus disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis risk, prognostic implications, and anticoagulation effects in COVID-19. We included 37 studies from 4070 unique citations. Meta-analysis was performed when feasible. Coagulopathy and thrombotic events were frequent among patients with COVID-19 and further increased in those with more severe forms of the disease. We also present guidance on the prevention and management of thrombosis from a multidisciplinary panel of specialists from Mayo Clinic. The current certainty of evidence is generally very low and continues to evolve.

PMID:33153635 | PMC:PMC7458092 | DOI:10.1016/j.mayocp.2020.08.030

Leave a Reply

Your email address will not be published.